The article compares revenue growth at Bristol Myers Squibb and Eli Lilly. Lilly's growth is driven by GLP-1 drugs: Mounjaro brought in $9.9 billion worldwide in Q2 (up 91% year over year), Zepbound $4.9 billion in U.S. sales, and the oral Foundayo, launched in April 2026, $98 million in its first quarter. Bristol Myers Squibb (BMY) has steadier revenue, with no GLP-1 drug on the market and reliance on Eliquis and Opdivo, and its growth portfolio made up 58% of Q2 revenue. The article notes Bristol Myers Squibb trades at about 9.4 times forward earnings versus almost 25 times for Lilly, and says Lilly's two main products account for nearly two-thirds of quarterly sales, a concentration and pricing risk to its growth. Both companies report third-quarter results on Oct. 29.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsEli LillyBristol Myers SquibbGLP-1
Open a keyword to see other news on the same topic.
Related news
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison of Amgen (AMGN) and Bristol Myers Squibb (BMY) uses FY 2025 financials. Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion (net margin around 21%) and free cash flow near $8.1 billion; BMY posted revenue of about $48.2 billion, nearly flat, net income of about $7.1 billion (net margin about 14.6%) and free cash flow of about $12.8 billion. The article notes Amgen faces drug pricing pressure, an ongoing IRS tax dispute and biosimilar competition, while BMY depends heavily on Eliquis and faces generic competition and government pricing constraints. It concludes BMY trades at a significantly lower valuation than Amgen, though much of its expected difficulty may already be priced in.
- Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Novo Nordisk presented a post hoc analysis of a Phase 3 CagriSema trial at The Menopause Society meeting: after 68 weeks, 2,309 women lost almost 25% of body weight on average, versus 3% on placebo. Among 1,902 women with menopause-related overweight or obesity, mean loss ranged from 23% to nearly 27%, while placebo averaged 2%. These results beat or match Wegovy (just under 15%) and Zepbound (nearly 21%), though in the head-to-head Redefine 4 trial, tirzepatide, Zepbound's molecule, showed similar or slightly higher efficacy, nearly 26% at the maximum dose. The author argues CagriSema is unlikely to win back market share from Eli Lilly, so investors should watch Novo's other pipeline programs, and notes the figures assume patients use the drug as directed.
- Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Leads Industry
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's Foundayo, an oral GLP-1 weight-loss medicine approved in the U.S. in April, is drawing new patients, with 80% of its prescriptions earlier this year going to people who had never taken a GLP-1 medicine before. The company's Onswik, a once-weekly basal insulin for diabetes approved in September, could strengthen its diabetes portfolio, though Novo Nordisk's Awiqli was approved first in March. The investigational retatrutide showed average weight loss of up to 28.3% over 80 weeks in one Phase 3 study, and Eli Lilly plans to submit it for regulatory approval in the first quarter of 2027. The article argues these drugs could power Eli Lilly's next phase of growth beyond Zepbound.
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly, once a steady insulin maker, became a major player in obesity drugs after tirzepatide, sold as Mounjaro and Zepbound, reshaped its business. A $1,000 investment ten years ago grew to $18,637 in share price terms, versus $3,634 for the S&P 500 over the same period, though these figures exclude dividends, which rose from $0.51 to $1.73 a quarter. Q2 2026 revenue rose 47.7% to $22.97 billion, and the company raised full-year guidance to $85.0–87.0 billion. Volume growth of 60% has more than offset a 13% fall in realized prices, while Lilly plans a U.S. filing for retatrutide in Q1 2027. The article notes shares fell about 22% between February 4 and April 30, 2026, before recovering.
Related markets
Latest news
- SoFi Launches Tokenized Deposit That Earns 4.4% and Converts to a Stablecoin
SoFi has launched SoFi Earn (SOFIE), which it calls the first national bank-issued tokenized deposit for consumers, with each token representing $1 held at SoFi Bank. Holders earn a 4.40% APY, and the funds are FDIC-insured up to applicable limits, unlike most stablecoins, while tokens can be converted one-to-one into SoFiUSD to buy crypto or move dollars on blockchain rails. Citing Federal Reserve research, SoFi says roughly $64 billion, about 21% of the stablecoin market, sits idle in forgotten or inactive wallets, and the product aims to keep that money earning. It is SoFi's fifth crypto product in under a year, following its late-2025 return to crypto trading with more than 40 tokens and the launch of SoFiUSD.
- Why Nvidia's new DSX POD could really benefit corporate America
Nvidia unveiled the DSX POD, a pre-built, pre-tested rack of chips that plugs into existing power and can get a data center running in as little as 14 days. The host says the 'AI factory in a shipping container' description is misleading, since the unit includes no building or power, and notes neoclouds often face a four-to-six-month gap between receiving chips and generating revenue. He argues the product may appeal more to corporate America, such as financial firms bringing data processing in-house and renting space for 20 racks, rather than relying on endless cloud bills.
- The UK needs a workable route to regulated DeFi access
Katie Harries, Coinbase's head of policy for Europe, argues that the FCA's proposed crypto rules could amount to a de facto ban on regulated firms providing access to DeFi. The FCA expects regulated platforms to execute customer orders only on FCA-authorized venues, but DeFi protocols have no authorized person behind them. The rules apply from October 2027, and the FCA is not writing DeFi-specific rules, applying the same standards as fully centralized trading. The author argues a ban would push activity beyond regulators' visibility, and that clear consumer information, firm responsibilities and customer consent before leaving a regulated platform would address the risks better. The article points to the EU, where ESMA has proposed allowing regulated firms to provide DeFi access, and the US, where the SEC granted an Innovation Exemption for peer-to-peer trading of tokenized stocks.
- SEEQC Demonstrates Quantum Error Correction Performance Gains with Industry First Digital Interface Optimized Decoder Architecture using NVIDIA Ising and NVQLink
SEEQC reported results from a simulated quantum processor showing that combining its chip-based pre-decoder with NVIDIA Ising, linked through SEEQC Digital Link and NVIDIA NVQLink, improved two key decoding metrics, latency and logical error rate, by approximately 50% compared with running NVIDIA Ising as a standalone pre-decoder. The company says these metrics dictate how well fault-tolerant quantum systems scale, and that specialized processing close to the QPU reduces the data sent to GPU-based classical compute. CEO John Levy said tight integration of quantum processors with HPC infrastructure will be key, while NVIDIA's Sam Stanwyck said open models and interfaces let quantum builders accelerate hardware with AI and GPUs. The next step is chip-to-chip integration of a quantum processor within advanced HPC infrastructure for quantum AI applications.
- Rockwell Automation Expands FactoryTalk Conductor with NVIDIA Nemotron Support
Rockwell Automation (NYSE: ROK) said its FactoryTalk Conductor AI orchestration platform now supports NVIDIA Nemotron open models, giving manufacturers more deployment options. The approach lets companies keep engineering and production data in their own environments and retain control over infrastructure, governance and cost, while still using Rockwell-verified agents and skills. The platform lets users start engineering tasks through natural language and points toward agent-driven workflows in which engineers remain responsible for oversight and critical decisions.
- Why Tesla shareholders should be 'a little bit nervous' about a SpaceX merger
Tesla and SpaceX have formed special committees to discuss a possible merger, which would be the largest in history, with SpaceX valued at about $2.2 trillion and Tesla at about $1.7 trillion. One speaker warns Tesla shareholders could swap into SpaceX at about 0.7 SpaceX shares per Tesla share before any premium, with Elon Musk holding about 82% of the vote, raising the question of whether Tesla would be folded in at a discount. Dave Nadig calls the committees theatrics given Musk's 79% voting control, and says the real concern is consolidating control in one person, which makes him skeptical the deal benefits shareholders, who are exposed through index funds regardless.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.